QuintilesIMS Announces Alliance with Salesforce to Build Next Generation Solutions for Life Sciences Firms — From Molecule to Market

April 24, 2017

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.

(Business Wire) QuintilesIMS (NYSE:Q), a leading provider of information, technology services and contract research to the life sciences industry, today announced an alliance with Salesforce, the world’s #1 CRM company and Intelligent Customer Success Platform, to offer life sciences companies new capabilities to move treatments more efficiently and effectively, from molecule to market.

As part of the alliance, QuintilesIMS is building new solutions on the Salesforce Platform, taking advantage of built-in cloud, mobile, social and artificial intelligence (AI) capabilities. These solutions — in addition to other products QuintilesIMS builds on the Salesforce Marketing Cloud — will help life science companies better manage clinical trials, accelerate patient recruitment, improve efficiency and effectiveness of marketing activities, as well as achieve other key commercial objectives as they bring new therapies to market and beyond.

“We are thrilled to align with QuintilesIMS to digitally transform the important work of life sciences companies together,” said Keith Block, vice chairman, president and COO, Salesforce. “Building on the Salesforce Intelligent Customer Success Platform, QuintilesIMS will create solutions that empower life sciences firms to collaborate with providers and patients, in smarter and more predictive ways, throughout the clinical life cycle.”

“This Salesforce collaboration furthers our strategy of building our solutions on a foundation of intelligent, technology-standard platforms. Using this approach, as well as continuous updates provided by the platform providers, we can better focus on our areas of differentiation, which deliver the greatest value and benefit to our customers,” said Kevin Knightly, president, Information & Technology Solutions, QuintilesIMS. “We believe this alliance with Salesforce has transformative potential for the life sciences industry as it will better equip and enable our customers to meet the clinical-to-commercial challenges they face as they move healthcare forward.”

While terms of the agreement have not been disclosed, it is a multi-year venture that will operate on a global scale.

“The future of healthcare is at stake in a digital world. Patient success requires co-innovation and co-creation among industry leaders,” said R "Ray" Wang, Principal Analyst and CEO, Constellation Research, Inc. “Only with this close level of partnership can true innovation emerge to transform patient outcomes.”

Salesforce and others are among the trademarks of salesforce.com, inc.

About QuintilesIMS

QuintilesIMS (NYSE:Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles Transnational and IMS Health, QuintilesIMS’s approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes through treatment innovations, care provision and access can leverage QuintilesIMS’s broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial, bringing customers a unique opportunity to realize the full potential of innovations and advanced healthcare outcomes.

As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, and to identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. To learn more, visit www.QuintilesIMS.com.

Click here to subscribe to Mobile Alerts for QuintilesIMS.

Contacts:

QuintilesIMS:
Tor Constantino, +1.484.567.6732
QuintilesIMS Media Relations
tor.constantino@quintilesims.com
or
Andrew Markwick, +1.973.257.7144
QuintilesIMS Investor Relations
andrew.markwick@quintilesims.com